Mumbai: Global pharma major Lupin Limited has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) ...

Liraglutide is an injectable prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults and children who are 10 years of age and older with type 2 diabetes ...

The product is bioequivalent to Novo Nordisk Inc's Victoza injection. It is indicated as an adjunct to diet and exercise to ...

Victoza (liraglutide) solution for injection is prescribed to help manage blood sugar and reduce major heart-related risks. Victoza is not safe to use while pregnant and may not be safe to use while ...

The product is bioequivalent to Novo Nordisk Inc.'s Victoza Injection, 18 mg/3 mL (6 mg/mL), and is indicated as an adjunct ...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), Monday announced the launch of an authorized generic for Victoza injection with a quantity of 1.8 mg for type 2 diabetes patients in the U.S.

Lupin has received approval from the Food and Drug Administration for liraglutide injection single-patient-use prefilled pens and glucagon for injection vials. Both of these products will be ...

Lupin launches Liraglutide Injection, a generic diabetes medication, in the US market. Aims to improve glycemic control.

Ozempic shortages expected throughout 2024 Victoza shortages expected until at least Q2 2024 Diabetes drug Ozempic used 'off label' to treat obesity Nov 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens ...